At the Thirteenth International Kidney Cancer Symposium, Dr Elizabeth Plimack (Fox Chase Cancer Center, PA) discusses prospective immunotherapy in kidney cancer management. Newer immunotherapeutic agents have demonstrated efficacy and are expected to be approved for kidney cancer soon. Collaborations between different drug manufactures have facilitated progress in combination therapies.
Advertisement Single Below Content
Advertisement Single Below Content
Advertisement Single Below Content